Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708744 · ClinicalTrials.gov registry record · Phase 1
A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers
A Phase 1 study, sponsored by Zosano Pharma Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT03708744: Completed Phase 1 study, sponsored by Zosano Pharma Corporation.
NCT03708744 is a Phase 1 study that has completed, run by Zosano Pharma Corporation. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03708744, a Phase 1 study, has completed, sponsored by Zosano Pharma Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis. Dosing will occur approximately 48 hours apart, until completion of dosing in randomized order per the treatment sequence tables. Plasma samples from the dosing days will be sent to the analytical laboratory for analysis and tolerability for each of the dose levels will be summarized. After completion of the four dosing days, subjects will be assessed one final time and dismissed from the study.
Primary Outcome
maximum observed plasma concentration
Interventions
- DRUG A: M207 3.8mg, 30 min, upper arm
- DRUG B: M207 3.8 mg, 30 min, thigh
- DRUG C: M207 3.8 mg, 1 hr, upper arm
- DRUG D:zolmitriptan nasal spray
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-11-01 |
| Est. Completion | 2018-11-20 |
| Phase | Phase 1 |
What the finished NCT03708744 record still lists
NCT03708744 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 4 interventions - of which A: M207 3.8mg, 30 min, upper arm is the first listed.
NCT03708744 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03708744 about?
NCT03708744 is a clinical study titled "A Study of M207 With Intranasal Zolmitriptan in Healthy Volunteers". This is a single-center, open-label, randomized, four-way crossover study. Each subject will receive each of the four study treatments once, followed by in-clinic monitoring and extensive blood sample collection for pharmacokinetic analysis. Dosing will occur approximately 48 hours apart, until com...
What is the current status of trial NCT03708744?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2018-11-01. Estimated completion is 2018-11-20.
What interventions are being tested in trial NCT03708744?
The interventions under investigation include: A: M207 3.8mg, 30 min, upper arm (DRUG), B: M207 3.8 mg, 30 min, thigh (DRUG), C: M207 3.8 mg, 1 hr, upper arm (DRUG), D:zolmitriptan nasal spray (DRUG).
Who is sponsoring clinical trial NCT03708744?
This trial is sponsored by Zosano Pharma Corporation, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03708744's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI